Cloud-based Healthcare Solutions Market

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of cloud-based solutions for drug discovery, development and manufacturing market and its likely evolution in the short-mid term and long term. 

Chapter 3 is an introductory chapter that presents details on implementation of cloud computing in pharmaceutical / biotech sector. It elaborates on the types of cloud and cloud services and provides an overview on applications of cloud-based solutions in drug discovery, development and drug manufacturing process, along with detailed information on its benefits and limitations. 

Chapter 4 provides a review of the current market landscape of companies offering cloud-based services, platforms, and tools for drug discovery, development and manufacturing. It includes a detailed analysis based on year of establishment, company size (in terms of number of employees), company type, location of headquarters, type of cloud (public, private, hybrid), type of service (IaaS, PaaS, SaaS), area of application (drug discovery, drug development, drug manufacturing), additional capabilities, additional services offered and quality certifications.

Chapter 5 features an in-depth analysis of the contemporary trends, highlighted through various schematic representations, including 4D bubble analysis based on type of service, area of application, company size and quality certifications, an insightful grid representation based on type of service, area of application, and type of cloud, a waffle chart based on geography and COVID-19-related initiatives, a mekko chart based on geography and additional capabilities and a world map representation highlighting the location of service providers.

Chapter 6 presents an insightful competitiveness analysis of the cloud-based solution providers, taking into consideration their supplier strength (in terms of experience of the service provider), and popularity index (in terms of type of cloud, type of service, area of application, additional capabilities, additional services offered, COVID-19-related initiatives, number of quality certifications, number of partnerships, number of followers on twitter, and Google hits), highlighting the prominent companies.

Chapter 7 include elaborate profiles of the key players that provide cloud-based solutions for drug discovery, development and manufacturing. Each company profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key members of the executive team), recent developments and an informed future outlook.

Chapter 8 features an analysis of the partnerships that have been inked by stakeholders in this domain, in the period between 2015 and 2020. It includes a brief description of various partnership models (namely clinical data management agreements, platform development / improvement agreements, research agreements, research and platform development agreements, regulatory process management agreements, technology / data integration agreements, and other agreements). In addition, it includes a detailed analysis of partnerships, based on year of partnership, type of partnership, location of partners and other relevant parameters.

Chapter 9 includes an insightful analysis highlighting the likely cost saving potential associated with the use of cloud-based solutions for drug discovery, development and manufacturing, taking into consideration various parameters, such as pharmaceutical R&D expenditure, drug discovery expenditure / budget, clinical trials expenditure, drug manufacturing expenditure and increase in efficiency by adoption of cloud-based solutions.

Chapter 10 includes estimate of the existing market size and the likely future opportunity within the cloud-based services for drug discovery, development and manufacturing market. It includes estimate on the financial evolution of the market, over the period 202012030. The chapter also provides details on the likely distribution of the current and forecasted opportunity across [A] type of cloud (private, public and hybrid) ), [B] type of service (infrastructure as a service (IaaS), platform as a service (PaaS), software as a service (SaaS)), [C] area of application (drug discovery, drug development and drug manufacturing) , [D] end user (biotech vendors, contract research organizations, pharmaceutical companies and others), and [E] key geographical regions (North America, Europe, Asia, Middle East and North Africa, Latin America and Rest of the World). In order to account for future uncertainties and to add robustness to forecast model, three scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth are provided in this chapter.

Chapter 11 provides an in-depth analysis of the opportunities and the overall cost savings associated with integration of key tools and technologies, such as artificial intelligence, deep learning, machine learning, and quantum computing with cloud-based solutions for pharmaceutical product development and manufacturing. Further, it provides a detailed analysis on ease of implementation and associated risk in integrating above-mentioned technologies, based on the trends highlighted in published literature and patents.

Chapter 12 is a summary of the overall report, wherein we have mentioned all the key facts and figures described in the previous chapters. The chapter also highlights the evolutionary trends that were identified during the course of the study and are expected to influence the future of this market.

Chapter 13 is a collection of interview transcripts of discussions held with key stakeholders in this industry. In this chapter, we have presented the details of our conversations held with Paolo Colombo (Vice President Growth, InSilicoTrials Technologies) and Velizar Natovski (Regional Manager North and South America, CloudSigma).

Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 15 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION 
3.1. Chapter Overview
3.2. Overview of Cloud Computing
3.2.1. Types of Clouds and Cloud Services
3.2.2. Cloud Computing in Drug Discovery, Development and Manufacturing
3.2.3. Benefits and Limitations of Cloud Computing 
3.3. Concluding Remarks

4. MARKET LANDSCAPE 
4.1. Chapter Overview

4.2. Cloud-based Solutions for Drug Discovery, Development and Manufacturing: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Company Type
4.2.4. Analysis by Location of Headquarters
4.2.5. Analysis by Quality Certifications
4.3. Cloud-based Solutions for Drug Discovery, Development and Manufacturing: Market Landscape
4.3.1. Analysis by Type of Cloud
4.3.2. Analysis by Type of Service
4.3.3. Analysis by Area of Application 
4.3.4. Analysis by Additional Capabilities
4.3.5. Analysis by Additional Services Offered

4.4. Cloud-based Solutions for Drug Discovery, Development and Manufacturing: COVID-19-related Initiatives
4.5. Cloud-based Solutions for Drug Discovery, Development and Manufacturing: Information on Additional Players

5. KEY INSIGHTS
5.1. Chapter Overview
5.2. Analysis by Type of Service, Area of Application, Company Size and Quality Certifications (4D Bubble Chart)
5.3. Analysis by Type of Service, Area of Application and Type of Cloud (Grid Representation)
5.4. Analysis by Geography and COVID-19-related Initiatives (Waffle Chart)
5.5. Analysis by Geography and Additional Capabilities (Mekko Chart)
5.6. Analysis by Location of Service Providers (World Map Representation)

6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Key Assumptions and Parameters
6.3. Methodology
6.3.1. Company Competitiveness Analysis: Small Companies
6.3.2. Company Competitiveness Analysis: Mid-Sized Companies
6.3.3. Company Competitiveness Analysis: Large Companies
6.4. Benchmarking the Capabilities of Leading Players

7. COMPANY PROFILES
7.1. Chapter Overview
7.2. Accenture
7.2.1. Company Overview
7.2.2. Recent Developments and Future Outlook

7.3. Alibaba Cloud
7.3.1. Company Overview
7.3.2. Recent Developments and Future Outlook

7.4. Amazon Web Services
7.4.1. Company Overview
7.4.2. Recent Developments and Future Outlook

7.5. Google 
7.5.1. Company Overview
7.5.2. Recent Developments and Future Outlook

7.6. IBM
7.6.1. Company Overview
7.6.2. Recent Developments and Future Outlook 

7.7. Nutanix
7.7.1. Company Overview
7.7.2. Recent Developments and Future Outlook 

7.8. XtalPi
7.8.1. Company Overview
7.8.2. Recent Developments and Future Outlook 

8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Types of Partnership Models

8.3. Cloud-based Solutions for Drug Discovery, Development and Manufacturing: Partnerships
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year and Type of Partnership
8.3.4. Analysis by Company Size and Type of Partnership

8.3.5. Analysis by Type of Partner
8.3.5.1. Analysis by Year of Partnership and Type of Partner
8.3.5.2. Analysis by Type of Partnership and Type of Partner
8.3.5.3. Analysis by Company Size and Type of Partner

8.3.6. Analysis by Area of Application 
8.3.6.1. Analysis by Year of Partnership and Area of Application
8.3.6.2. Analysis by Type of Partnership and Area of Application

8.3.7. Most Active Players: Analysis by Number of Partnerships
8.3.8. Regional Analysis
8.3.8.1. Intercontinental and Intracontinental Agreements
8.3.8.2. Local and International Agreements

9. COST SAVING ANALYSIS
9.1. Chapter Overview
9.2. Key Assumptions and Methodology

9.3. Overall Cost Saving Potential of Using Cloud-based Solutions for Drug Discovery, Development and Manufacturing 2021-2030
9.3.1. Likely Cost Savings in Drug Discovery, 2021-2030
9.3.2. Likely Cost Savings in Drug Development, 2021-2030
9.3.3. Likely Cost Savings in Drug Manufacturing, 2021-2030

9.4. Overall Cost Saving Potential of Using Cloud-based Solutions across Different Geographies, 2021 and 2030
9.4.1. Likely Cost Savings in North America, 2021-2030
9.4.2. Likely Cost Savings in Europe, 2021-2030
9.4.3. Likely Cost Savings in Asia, 2021-2030
9.4.4. Likely Cost Savings in Middle East and North Africa, 2021-2030
9.4.5. Likely Cost Savings in Latin America, 2021-2030
9.4.6. Likely Cost Savings in Rest of the World, 2021-2030

9.5. Concluding Remarks: Cost Saving Scenarios

10. MARKET FORECAST
10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Global Cloud-based Solutions for Drug Discovery, Development and Manufacturing Market, 2021-2030

10.4. Cloud-based Solutions Market: Distribution by Type of Cloud
10.4.1. Cloud-based Solutions Market for Private Cloud, 2021-2030
10.4.2. Cloud-based Solutions Market for Public Cloud, 2021-2030
10.4.3. Cloud-based Solutions Market for Hybrid Cloud, 2021-2030

10.5. Cloud-based Solutions Market: Distribution by Type of Service
10.5.1. Cloud-based Solutions Market for Infrastructure as a Service (IaaS), 2021-2030
10.5.2. Cloud-based Solutions Market for Platform as a Service (PaaS), 2021-2030
10.5.3. Cloud-based Solutions Market for Software as a Service (SaaS), 2021-2030

10.6. Cloud-based Solutions Market: Distribution by Area of Application
10.6.1. Cloud-based Solutions Market for Drug Discovery, 2021-2030
10.6.2. Cloud-based Solutions Market for Drug Development, 2021-2030
10.6.3. Cloud-based Solutions Market for Drug Manufacturing, 2021-2030

10.7. Cloud-based Solutions Market: Distribution by End-User
10.7.1. Cloud-based Solutions Market for Biotech Vendors, 2021-2030
10.7.2. Cloud-based Solutions Market for Contract Research Organizations, 2021-2030
10.7.3. Cloud-based Solutions Market for Pharmaceutical Companies, 2021-2030
10.7.4. Cloud-based Solutions Market for Others, 2021-2030

10.8. Cloud-based Solutions Market: Distribution by Geography
10.8.1. Cloud-based Solutions Market in North America, 2021-2030
10.8.2. Cloud-based Solutions Market in Europe, 2021-2030
10.8.3. Cloud-based Solutions Market in Asia-Pacific, 2021-2030
10.8.4. Cloud-based Solutions Market in Middle East and North Africa, 2021-2030
10.8.5. Cloud-based Solutions Market in Latin America, 2021-2030
10.8.6. Cloud-based Solutions Market in Rest of the World, 2021-2030

10.9. Cloud-based Solutions Market: Distribution by Area of Application and Geography
10.9.1. Cloud-based Solutions Market for Drug Discovery in North America, 2021-2030
10.9.2. Cloud-based Solutions Market for Drug Discovery in Europe, 2021-2030
10.9.3. Cloud-based Solutions Market for Drug Discovery in Asia-Pacific, 2021-2030
10.9.4. Cloud-based Solutions Market for Drug Discovery in Middle East and North Africa, 2021-2030
10.9.5. Cloud-based Solutions Market for Drug Discovery in Latin America, 2021-2030
10.9.6. Cloud-based Solutions Market for Drug Discovery in Rest of the World, 2021-2030

10.9.7. Cloud-based Solutions Market for Drug Development in North America, 2021-2030
10.9.8. Cloud-based Solutions Market for Drug Development in Europe, 2021-2030
10.9.9. Cloud-based Solutions Market for Drug Development in Asia-Pacific, 2021-2030
10.9.10. Cloud-based Solutions Market for Drug Development in Middle East and North Africa, 2021-2030
10.9.11. Cloud-based Solutions Market for Drug Development in Latin America, 2021-2030
10.9.12. Cloud-based Solutions Market for Drug Development in Rest of the World, 2021-2030

10.9.13. Cloud-based Solutions Market for Drug Manufacturing in North America, 2021-2030
10.9.14. Cloud-based Solutions Market for Drug Manufacturing in Europe, 2021-2030
10.9.15. Cloud-based Solutions Market for Drug Manufacturing in Asia-Pacific, 2021-2030
10.9.16. Cloud-based Solutions Market for Drug Manufacturing in Middle East and North Africa, 2021-2030
10.9.17. Cloud-based Solutions Market for Drug Manufacturing in Latin America, 2021-2030
10.9.18. Cloud-based Solutions Market for Drug Manufacturing in Rest of the World, 2021-2030
10.10. Concluding Remarks

11. ANTICIPATED TECHNOLOGY UPGRADES AFFILIATED OPPORTUNITIES
11.1. Chapter Overview
11.2. Scope and Methodology

11.3. Key Tools and Technologies
11.3.1. Artificial Intelligence
11.3.1.1. Artificial Intelligence in Pharmaceutical Product Development and Manufacturing
11.3.1.2. Likely Cost-Savings by Integrating Artificial Intelligence with Cloud Computing

11.3.2. Deep Learning
11.3.2.1. Deep Learning in Pharmaceutical Product Development and Manufacturing
11.3.2.2. Likely Cost-Savings by Integrating Deep Learning with Cloud Computing

11.3.3. Machine Learning
11.3.3.1. Machine Learning in Pharmaceutical Product Development and Manufacturing
11.3.3.2. Likely Cost-Savings by Integrating Machine Learning with Cloud Computing

11.3.4. Quantum Computing
11.3.4.1. Quantum Computing in Pharmaceutical Product Development and Manufacturing
11.3.4.2. Likely Cost-Savings by Integrating Quantum Computing with Cloud Computing

11.4. Ease of Implementation and Associated Risk Analysis 
11.4.1. Key Assumptions and Methodology
11.4.2. Results and Discussion 

12. CONCLUSION
12.1. Chapter Overview
12.2. Key Takeaways

13. EXECUTIVE INSIGHTS
13.1. Chapter Overview
13.2. CloudSigma
13.2.1. Company Snapshot
13.2.2. Interview Transcript: Velizar Natovski, Regional Manager North and South America
13.3. InSilicoTrials
13.3.1. Company Snapshot
13.3.2. Interview Transcript: Paolo Colombo, Vice President Growth

14. APPENDIX I: TABULATED DATA

15. APPENDIX II: LIST OF COMPANIES AND ORGANIZATION

List Of Figures

Figure 3.1 Components of Cloud Computing
Figure 3.2 Applications of Cloud Computing
Figure 3.3 Key Benefits and Limitations of Cloud Computing
Figure 4.1 Cloud-based Solution Providers: Distribution by Year of Establishment
Figure 4.2 Cloud-based Solution Providers: Distribution by Company Size
Figure 4.3 Cloud-based Solution Providers: Distribution by Type of Company
Figure 4.4 Cloud-based Solution Providers: Distribution by Location of Headquarters
Figure 4.5 Cloud-based Solutions: Distribution by Quality Certifications
Figure 4.6 Cloud-based Solutions: Distribution by Type of Cloud
Figure 4.7 Cloud-based Solutions: Distribution by Type of Service
Figure 4.8 Cloud-based Solutions: Distribution by Area of Application
Figure 4.9 Cloud-based Solutions: Distribution by Additional Capabilities
Figure 4.10 Cloud-based Solutions: Distribution by Additional Services Offered
Figure 5.1 4D Bubble Chart Representation: Distribution by Type of Service, Area of Application, Company Size and Quality Certifications
Figure 5.2 Grid Representation: Distribution by Type of Service, Area of Application and Type of Cloud
Figure 5.3 Waffle Chart Representation: Distribution by Geography and COVID-19-related Initiatives
Figure 5.4 Mekko Chart Representation: Distribution by Geography and Additional Capabilities
Figure 5.5 World Map Representation: Distribution by Location of Service Providers
Figure 6.1 Company Competitiveness Analysis: Small Companies
Figure 6.2 Company Competitiveness Analysis: Mid-Sized Companies
Figure 6.3 Company Competitiveness Analysis: Large Companies
Figure 6.4 Leading Cloud-based Solution Providers for Drug Discovery, Development and Manufacturing
Figure 8.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2015-2020
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Year-Wise Distribution by Type of Partnership
Figure 8.4 Partnerships and Collaborations: Distribution by Company Size and Type of Partnership
Figure 8.5 Partnerships and Collaborations: Distribution by Type of Partner
Figure 8.6 Partnerships and Collaborations: Year-Wise Distribution by Type of Partner
Figure 8.7 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 8.8 Partnerships and Collaborations: Distribution by Company Size and Type of Partner
Figure 8.9 Partnerships and Collaborations: Distribution by Area of Application
Figure 8.10 Partnerships and Collaborations: Year-Wise Distribution by Area of Application
Figure 8.11 Partnerships and Collaborations: Distribution by Type of Partnership and Area of Application
Figure 8.12 Most Active Players: Distribution by Number of Partnerships
Figure 8.13 Partnerships and Collaborations: Regional Distribution
Figure 8.14 Partnerships and Collaborations: Country-Wise Distribution
Figure 8.15 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 9.1 Overall Cost Saving Potential of Using Cloud-based Solutions for DrugDiscovery, Development and Manufacturing, 2021-2030 (USD Million)
Figure 9.2 Likely Cost Savings associated with the Use of Cloud-based Solutions for DrugDiscovery, 2021-2030 (USD Million)
Figure 9.3 Likely Cost Savings associated with the Use of Cloud-based Solutions for DrugDevelopment, 2021-2030 (USD Million)
Figure 9.4 Likely Cost Savings associated with the Use of Cloud-based Solutions for DrugManufacturing, 2021-2030 (USD Million)
Figure 9.5 Overall Cost Saving Potential of Using Cloud-based Solutions across DifferentGeographies, 2021 and 2030
Figure 9.6 Likely Cost Savings associated with the Use of Cloud-based Solutions in NorthAmerica, 2021-2030 (USD Million)
Figure 9.7 Likely Cost Savings associated with the Use of Cloud-based Solutions inEurope, 2021-2030 (USD Million)
Figure 9.8 Likely Cost Savings associated with the Use of Cloud-based Solutions in Asia,2021-2030 (USD Million)
Figure 9.9 Likely Cost Savings associated with the Use of Cloud-based Solutions in MiddleEast and North Africa, 2021-2030 (USD Million)
Figure 9.10 Likely Cost Savings associated with the Use of Cloud-based Solutions in LatinAmerica, 2021-2030 (USD Million)
Figure 9.11 Likely Cost Savings associated with the Use of Cloud-based Solutions in Rest ofthe World, 2021-2030 (USD Million)
Figure 9.12 Likely Cost Savings associated with the Use of Cloud-based Solutions in Drug Discovery, Development and Manufacturing, 2021, 2025 and 2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Figure 10.1 Global Cloud-based Solutions for Drug Discovery, Development and Manufacturing Market, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Figure 10.2 Cloud-based Solutions Market: Distribution by Type of Cloud, 2021 and 2030
Figure 10.3 Cloud-based Solutions Market for Private Cloud, 2021-2030 (USD Million)
Figure 10.4 Cloud-based Solutions Market for Public Cloud, 2021-2030 (USD Million)
Figure 10.5 Cloud-based Solutions Market for Hybrid Cloud, 2021-2030 (USD Million)
Figure 10.6 Cloud-based Solutions Market: Distribution by Type of Service, 2021 and 2030
Figure 10.7 Cloud-based Solutions Market for Infrastructure as a Service (IaaS), 2021-2030 (USD Million)
Figure 10.8 Cloud-based Solutions Market for Platform as a Service (PaaS), 2021-2030 (USD Million)
Figure 10.9 Cloud-based Solutions Market for Software as a Service (SaaS), 2021-2030 (USD Million)
Figure 10.10 Cloud-based Solutions Market: Distribution by Area of Application, 2021 and 2030
Figure 10.11 Cloud-based Solutions Market for Drug Discovery, 2021-2030 (USD Million)
Figure 10.12 Cloud-based Solutions Market for Drug Development, 2021-2030 (USD Million)
Figure 10.13 Cloud-based Solutions Market for Drug Manufacturing, 2021-2030 (USD Million)
Figure 10.14 Cloud-based Solutions Market: Distribution by End-User, 2021 and 2030
Figure 10.15 Cloud-based Solutions Market for Biotech Vendors, 2021-2030 (USD Million)
Figure 10.16 Cloud-based Solutions Market for Contract Research Organizations, 2021-2030 (USD Million)
Figure 10.17 Cloud-based Solutions Market for Pharmaceutical Companies, 2021-2030 (USD Million)
Figure 10.18 Cloud-based Solutions Market for Others, 2021-2030 (USD Million)
Figure 10.19 Cloud-based Solutions Market: Distribution by Geography, 2021 and 2030
Figure 10.20 Cloud-based Solutions Market in North America, 2021-2030 (USD Million)
Figure 10.21 Cloud-based Solutions Market in Europe, 2021-2030 (USD Million)
Figure 10.22 Cloud-based Solutions Market in Asia, 2021-2030 (USD Million)
Figure 10.23 Cloud-based Solutions Market in Middle East and North Africa, 2021-2030 (USD Million)
Figure 10.24 Cloud-based Solutions Market in Latin America, 2021-2030 (USD Million)
Figure 10.25 Cloud-based Solutions Market in Rest of the World, 2021-2030 (USD Million)
Figure 10.26 Cloud-based Solutions Market: Distribution by Area of Application and Geography
Figure 10.27 Cloud-based Solutions Market for Drug Discovery in North America, 2021-2030 (USD Million)
Figure 10.28 Cloud-based Solutions Market for Drug Discovery in Europe, 2021-2030 (USD Million)
Figure 10.29 Cloud-based Solutions Market for Drug Discovery in Asia, 2021-2030 (USD Million)
Figure 10.30 Cloud-based Solutions Market for Drug Discovery in Middle East and North Africa, 2021-2030 (USD Million)
Figure 10.31 Cloud-based Solutions Market for Drug Discovery in Latin America, 2021-2030 (USD Million)
Figure 10.32 Cloud-based Solutions Market for Drug Discovery in Rest of the World, 2021-2030 (USD Million)
Figure 10.33 Cloud-based Solutions Market for Drug Development in North America, 2021-2030 (USD Million)
Figure 10.34 Cloud-based Solutions Market for Drug Development in Europe, 2021-2030 (USD Million)
Figure 10.35 Cloud-based Solutions Market for Drug Development in Asia, 2021-2030 (USD Million)
Figure 10.36 Cloud-based Solutions Market for Drug Development in Middle East and North Africa, 2021-2030 (USD Million)
Figure 10.37 Cloud-based Solutions Market for Drug Development in Latin America, 2021-2030 (USD Million)
Figure 10.38 Cloud-based Solutions Market for Drug Development in Rest of the World, 2021-2030 (USD Million)
Figure 10.39 Cloud-based Solutions Market for Drug Manufacturing in North America, 2021-2030 (USD Million)
Figure 10.40 Cloud-based Solutions Market for Drug Manufacturing in Europe, 2021-2030 (USD Million)
Figure 10.41 Cloud-based Solutions Market for Drug Manufacturing in Asia, 2021-2030 (USD Million)
Figure 10.42 Cloud-based Solutions Market for Drug Manufacturing in Middle East and North Africa, 2021-2030 (USD Million)
Figure 10.43 Cloud-based Solutions Market for Drug Manufacturing in Latin America, 2021-2030 (USD Million)
Figure 10.44 Cloud-based Solutions Market for Drug Manufacturing in Rest of theWorld, 2021-2030 (USD Million)
Figure 10.45 Global Cloud-based Solutions for Drug Discovery, Development, andManufacturing Market, 2021, 2025 and 2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Figure 11.1 Likely Cost Savings in Drug Discovery, Development, andManufacturing by Integrating Artificial Intelligence with Cloud Computing
Figure 11.2 Likely Cost Savings in Drug Discovery, Development, andManufacturing by Integrating Deep Learning with Cloud Computing
Figure 11.3 Likely Cost Savings in Drug Discovery, Development, andManufacturing by Integrating Machine Learning with Cloud Computing
Figure 11.4 Likely Cost Savings in Drug Discovery, Development, andManufacturing by Integrating Quantum Computing with Cloud Computing
Figure 11.5 Trends in Intellectual Property related to Integration of Key Tools andTechnologies with Cloud Computing for Drug Discovery, Development, and Manufacturing
Figure 11.6 Ease of Implementation and Associated Risk Analysis for Integration of KeyTools and Technologies with Cloud Computing for Drug Discovery, Development and Manufacturing
Figure 12.1 Concluding Remarks: Current Market Landscape
Figure 12.2 Concluding Remarks: Partnerships and Collaborations
Figure 12.3 Concluding Remarks: Cost Saving Analysis
Figure 12.4 Concluding Remarks: Market Forecast

List Of Tables

Table 4.1 Cloud-based Solution Providers: Information on Year of Establishment, Company Size, Company Type and Location of Headquarters
Table 4.2 Cloud-based Solution Providers: Information on Quality Certifications
Table 4.3 Cloud-based Solutions: Information on Type of Cloud and Type of Service
Table 4.4 Cloud-based Solutions: Information on Area of Application
Table 4.5 Cloud-based Solutions: Information on Additional Capabilities
Table 4.6 Cloud-based Solutions: Information on Additional Services Offered and COVID-19 Initiatives
Table 7.1 Cloud-based Solution Providers: List of Companies Profiled
Table 7.2 Accenture: Company Snapshot
Table 7.3 Accenture: Recent Developments and Future Outlook
Table 7.4 Alibaba Cloud: Company Snapshot
Table 7.5 Alibaba Cloud: Recent Developments and Future Outlook
Table 7.6 Amazon Web Services: Company Snapshot
Table 7.7 Amazon Web Services: Recent Developments and Future Outlook
Table 7.8 Google: Company Snapshot
Table 7.9 Google: Recent Developments and Future Outlook
Table 7.10 IBM: Company Snapshot
Table 7.11 IBM: Recent Developments and Future Outlook
Table 7.12 Nutanix: Company Snapshot
Table 7.13 Nutanix: Recent Developments and Future Outlook
Table 7.14 XtalPi: Company Snapshot
Table 7.15 XtalPi: Recent Developments and Future Outlook
Table 8.1 Cloud-based Solutions: List of Collaborations, 2015-2020
Table 8.2 Cloud-based Solutions: Partnerships and Collaborations, Information on Type of Partner and Type of Agreement, 2015-2020
Table 13.1 CloudSigma: Company Snapshot
Table 13.2 InSilicoTrials Technologies: Company Snapshot
Table 14.1 Cloud-based Solution Providers: Distribution by Year of Establishment
Table 14.2 Cloud-based Solution Providers: Distribution by Company Size
Table 14.3 Cloud-based Solution Providers: Distribution by Type of Company
Table 14.4 Cloud-based Solution Providers: Distribution by Location of Headquarters
Table 14.5 Cloud-based Solutions: Distribution by Quality Certifications
Table 14.6 Cloud-based Solutions: Distribution by Type of Cloud
Table 14.7 Cloud-based Solutions: Distribution by Type of Service
Table 14.8 Cloud-based Solutions: Distribution by Area of Application
Table 14.9 Cloud-based Solutions: Distribution by Additional Capabilities
Table 14.10 Cloud-based Solutions: Distribution by Additional Services Offered
Table 14.11 Distribution by Type of Service, Area of Application, Company Size and Quality Certifications (4D Bubble Chart)
Table 14.12 Distribution by Type of Service, Area of Application and Type of Cloud (Grid Representation)
Table 14.13 Distribution by Geography and COVID-19-related Initiatives (Waffle Chart)
Table 14.14 Distribution by Geography and Additional Capabilities (Mekko Chart)
Table 14.15 Distribution by Location of Service Providers (World Map Representation)
Table 14.16 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2015-2020
Table 14.17 Partnerships and Collaborations: Distribution by Type of Partnership
Table 14.18 Partnerships and Collaborations: Year-Wise Trend by Type of Partnership
Table 14.19 Partnerships and Collaborations: Distribution by Company Size and Type of Partnership
Table 14.20 Partnerships and Collaborations: Distribution by Type of Partner
Table 14.21 Partnerships and Collaborations: Year-Wise Trend by Type of Partner
Table 14.22 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 14.23 Partnerships and Collaborations: Distribution by Company Size and Type of Partner
Table 14.24 Partnerships and Collaborations: Distribution by Area of Application
Table 14.25 Partnerships and Collaborations: Year-Wise Trend by Area of Application
Table 14.26 Partnerships and Collaborations: Distribution by Type of Partnership and Area of Application
Table 14.27 Most Active Players: Distribution by Number of Partnerships
Table 14.28 Partnerships and Collaborations: Regional Distribution
Table 14.29 Partnerships and Collaborations: Country-Wise Distribution
Table 14.30 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 14.31 Overall Cost Saving Potential of Using Cloud-based Solutions for DrugDiscovery, Development and Manufacturing 2021-2030 (USD Million)
Table 14.32 Likely Cost Savings associated with the Use of Cloud-based Solutions for DrugDiscovery, 2021-2030 (USD Million)
Table 14.33 Likely Cost Savings associated with the Use of Cloud-based Solutions for DrugDevelopment, 2021-2030 (USD Million)
Table 14.34 Likely Cost Savings associated with the Use of Cloud-based Solutions for DrugManufacturing, 2021-2030 (USD Million)
Table 14.35 Overall Cost Saving Potential of Using Cloud-based Solutions across DifferentGeographies, 2021 and 2030
Table 14.36 Likely Cost Savings associated with the Use of Cloud-based Solutions in NorthAmerica, 2021-2030 (USD Million)
Table 14.37 Likely Cost Savings associated with the Use of Cloud-based Solutions inEurope, 2021-2030 (USD Million)
Table 14.38 Likely Cost Savings associated with the Use of Cloud-based Solutions in Asia,2021-2030 (USD Million)
Table 14.39 Likely Cost Savings associated with the Use of Cloud-based Solutions in MiddleEast and North Africa, 2021-2030 (USD Million)
Table 14.40 Likely Cost Savings associated with the Use of Cloud-based Solutions in LatinAmerica, 2021-2030 (USD Million)
Table 14.41 Likely Cost Savings associated with the Use of Cloud-based Solutions in Rest ofthe World, 2021-2030 (USD Million)
Table 14.42 Likely Cost Savings associated with the Use of Cloud-based Solutions in Drug Discovery, Development and Manufacturing, 2021, 2025 and 2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 14.43 Global Cloud-based Solutions for Drug Discovery, Development and Manufacturing Services Market, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 14.44 Cloud-based Solutions Market: Distribution by Type of Cloud, 2021 and 2030
Table 14.45 Cloud-based Solutions Market for Private Cloud, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.46 Cloud-based Solutions Market for Public Cloud, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.47 Cloud-based Solutions Market for Hybrid Cloud, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.48 Cloud-based Solutions Market: Distribution by Type of Service, 2021 and 2030
Table 14.49 Cloud-based Solutions Market for Infrastructure as a Service (IaaS), 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.50 Cloud-based Solutions Market for Platform as a Service (PaaS), 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.51 Cloud-based Solutions Market for Software as a Service (SaaS), 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.52 Cloud-based Solutions Market: Distribution by Area of Application, 2021 and 2030
Table 14.53 Cloud-based Solutions Market for Drug Discovery, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.54 Cloud-based Solutions Market for Drug Development, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.55 Cloud-based Solutions Market for Drug Manufacturing, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.56 Cloud-based Solutions Market: Distribution by End-User, 2021 and 2030
Table 14.57 Cloud-based Solutions Market for Biotech Vendors, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.58 Cloud-based Solutions Market for Contract Research Organizations, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.59 Cloud-based Solutions Market for Pharmaceutical Companies, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.60 Cloud-based Solutions Market for Others, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.61 Cloud-based Solutions Market: Distribution by Geography, 2021 and 2030
Table 14.62 Cloud-based Solutions Market in North America, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.63 Cloud-based Solutions Market in Europe, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.64 Cloud-based Solutions Market in Asia, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.65 Cloud-based Solutions Market in Middle East and North Africa, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.66 Cloud-based Solutions Market in Latin America, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.67 Cloud-based Solutions Market in Rest of the World, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.68 Cloud-based Solutions Market: Distribution by Area of Application and Geography
Table 14.69 Cloud-based Solutions Market for Drug Discovery in North America, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.70 Cloud-based Solutions Market for Drug Discovery in Europe, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.71 Cloud-based Solutions Market for Drug Discovery in Asia, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.72 Cloud-based Solutions Market for Drug Discovery in Middle East and North Africa, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.73 Cloud-based Solutions Market for Drug Discovery in Latin America, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.74 Cloud-based Solutions Market for Drug Discovery in Rest of the World, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.75 Cloud-based Solutions Market for Drug Development in North America, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.76 Cloud-based Solutions Market for Drug Development in Europe, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.77 Cloud-based Solutions Market for Drug Development in Asia, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.78 Cloud-based Solutions Market for Drug Development in Middle East and North Africa, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.79 Cloud-based Solutions Market for Drug Development in Latin America, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.80 Cloud-based Solutions Market for Drug Development in Rest of the World, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.81 Cloud-based Solutions Market for Drug Manufacturing in North America, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.82 Cloud-based Solutions Market for Drug Manufacturing in Europe, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.83 Cloud-based Solutions Market for Drug Manufacturing in Asia, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.84 Cloud-based Solutions Market for Drug Manufacturing in Middle East and North Africa, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.85 Cloud-based Solutions Market for Drug Manufacturing in Latin America, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.86 Cloud-based Solutions Market for Drug Manufacturing in Rest of theWorld, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.87 Global Cloud-based Solutions for Drug Discovery, Development andManufacturing Services Market, 2021, 2025 and 2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 14.88 Likely Cost Savings in Drug Discovery, Development andManufacturing by Integrating Artificial Intelligence with Cloud Computing
Table 14.89 Likely Cost Savings in Drug Discovery, Development andManufacturing by Integrating Deep Learning with Cloud Computing
Table 14.90 Likely Cost Savings in Drug Discovery, Development andManufacturing by Integrating Machine Learning with Cloud Computing
Table 14.91 Likely Cost Savings in Drug Discovery, Development andManufacturing by Integrating Quantum Computing with Cloud Computing
Table 14.92 Trends in Intellectual Property related to Integration of Key Tools andTechnologies with Cloud Computing for Drug Discovery, Development and Manufacturing
Table 14.93 Ease of Implementation and Associated Risk Analysis for Integration of Key Tools and Technologies with Cloud Computing for Drug Discovery, Development and Manufacturing

List Of Companies

The following companies and organizations have been mentioned in the report.

1. 5Y Capital
2. A4A ARLENE FOR ALZHEIMER'S 
3. Accelagen
4. Accenture
5. Acelot
6. Albany Molecular Research
7. Alibaba Group
8. Alnylam Pharmaceuticals
9. Amazon Web Services
10. Apriorit 
11. ArisGlobal
12. Arithmos 
13. Arocom IT Solutions 
14. Asklepion Pharmaceuticals
15. Axcella Health
16. Axsome Therapeutics
17. Bayer Pharmaceuticals
18. Beacon Targeted Therapies
19. Beaconcure
20. Beijing Institute of Genomics
21. Benchling
22. BioAscent
23. Bioclinica
24. BioTel Research
25. BioXcel
26. Box 
27. C4X Discovery
28. CANbridge Pharmaceuticals
29. Cancer Research UK
30. Captario
31. Carolinas IT
32. Catalyst UX 
33. Celltrion
34. Centrexion Therapeutics
35. ChemAxon
36. China Life Healthcare Fund
37. Cisco Systems
38. Citeline
39. Clarivate Analytics
40. ClinStatDevice
41. Cloud Pharmaceuticals
42. CloudEndure
43. Cloudera
44. CloudSigma
45. Cloudways
46. Collaborative Drug Discovery 
47. Collective Scientific
48. Cyclica
49. Dassault Systèmes
50. Databricks
51. DataRow 
52. DC Health
53. Debiopharm 
54. DeepCure
55. DigitalOcean
56. dinCloud
57. DM Systems 
58. Dotmatics
59. DXC Technology
60. ELEKS
61. Eli Lilly
62. Elligo Health Research
63. Elucidata
64. Envisagenics 
65. Equinix
66. Euretos
67. Excelra
68. Exponential-e
69. FinTech Academy
70. Fitbit
71. Fosun Pharma
72. Fraunhofer-Chalmers Research Centre for Industrial Mathematics
73. German Cancer Research Center (DKFZ)
74. GlaxoSmithKline
75. Google
76. Graphene Services 
77. Hewlett Packard Enterprise
78. Huawei
79. IBM
80. IDsManager 
81. Infoblox
82. Informatica
83. Infosys
84. Infovity
85. Innovenn
86. InSilicoTrials
87. Instana
88. Iperion Life Sciences
89. Ipsen
90. IQVIA
91. Johnson & Johnson
92. J-STAR Research 
93. Kametera
94. Lab Asset Manager
95. LEO Pharma
96. LEXMA Technology
97. Limestone
98. Linode
99. Liquid Web
100. Looker Data Sciences
101. LumaCyte
102. Lundbeck
103. MassiveGrid
104. Melbourne Biomedical Precinct
105. Microsoft
106. Mind the Byte
107. Mistral Venture Partners
108. Moderna
109. National Institutes of Health
110. NextDocs 
111. Nimbix
112. NNIT Group
113. NNIT GROUP Johns Hopkins University
114. Nord cloud 
115. Novartis
116. Nutanix
117. Onix
118. OpenEye Scientific
119. OpenNebula Systems
120. Oracle
121. Parexel International 
122. Peachtree BioResearch Solutions
123. PerkinElmer
124. Pfizer
125. Pharma IT
126. PhoreMost
127. PICC Capital Investment Management
128. Pivot Park Screening Centre 
129. Pivotal
130. Porton Pharma Solutions
131. Prognos Health
132. Pronutria Biosciences 
133. QMENTA 
134. Rackspace
135. Red Dwarf 
136. Red Hat 
137. RedHill Biopharma
138. Regeneron Pharmaceuticals
139. Rescale
140. Reverie Labs
141. Rishabh Software
142. RMON Networks
143. Roche
144. RockStep Solutions
145. Saama Technologies
146. Sanofi
147. SAP
148. SAS 
149. ScaleMatrix
150. SciCord
151. Selcia
152. Server Today
153. Serverspace
154. ServiceNow
155. Servier
156. Signiant
157. SiteGround
158. Skyland Analytics
159. SoftBank
160. Software Builder
161. Soterius
162. Strateos
163. Sumitomo Dainippon Pharma
164. SureClinical
165. Synthace
166. Takeda Pharmaceutical
167. Tata Consultancy Services
168. Tencent Cloud
169. Teva Pharmaceuticals
170. Valo Health
171. VCA-Plus
172. Veeva Systems
173. VERSE Solutions
174. Vium
175. VmWare
176. Vultr
177. Wipro
178. WP Engine
179. WuXi AppTec
180. XenoGesis 
181. XtalPi
182. YASH Technologies
183. YPrime
184. ZNet Technologies

Source 1: www.lshtm.ac.uk/newsevents/news/2020/average-cost-developing-new-drug-could-be-15-billion-less-pharmaceutical#:~:text=The%20study%20estimated%20that%20the,as%20high%20as%20%242.8%20billion
Source 2: digital.hbs.edu/platform-digit/submission/astrazeneca-ai-in-drug-discovery-development